Publications by authors named "John Katsantonis"
Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
J Eur Acad Dermatol Venereol
June 2024
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment
Article Synopsis
- Psoriasis is a chronic condition, and switching treatment options is common for patients who don't respond well to initial therapies, particularly for those with more severe disease.
- Patients who switch biologics may develop anti-drug antibodies, which could reduce the effectiveness of future treatments.
- An observational study of five patients with severe plaque psoriasis showed that after switching from brodalumab to adalimumab and then back to brodalumab, patients experienced a significant return of efficacy, improving both skin and joint symptoms.
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Dermatol Ther
December 2022
Article Synopsis
- Brodalumab has shown significant clinical effectiveness and a good safety record in controlled trials, but limited real-world data exists; the BrIDGE study in Greece aims to fill this gap by observing treatment outcomes in moderate-to-severe plaque psoriasis patients over 104 weeks.* -
- Early results from the study, covering 12-16 weeks post-treatment initiation, indicate that 72.8% of patients achieved a "clear/almost clear" skin rating, with varying percentages reaching significant reductions in psoriasis severity scores (PASI75, PASI90, PASI100).* -
- Improvements in symptoms and quality of life were noted alongside a high treatment adherence rate of 90%, and while nine adverse events were recorded, the
Article Synopsis
- Real-world analysis evaluated the long-term benefits of brodalumab for treating moderate-to-severe psoriasis in 180 Greek patients over 24 months.
- The study showed significant improvements in psoriasis severity (measured by PASI scores) and quality of life (measured by DLQI scores) from baseline, with high proportions of patients achieving major reductions in PASI scores as early as 1 month into treatment.
- Overall, the findings support brodalumab's effectiveness in standard clinical practice, highlighting its rapid and sustained positive impact on patients' conditions.
Maculopapular Cutaneous Mastocytosis Successfully Treated with Omalizumab.
Acta Dermatovenerol Croat
April 2021
Dear Editor, Maculopapular cutaneous mastocytosis (MPCM), formerly telangiectasia macularis eruptiva perstans (TMEP), is an uncommon form of cutaneous mastocytosis first described on 1930 (1). It is more frequent in adults, and early diagnosis is crucial since it has been reported to be associated with serious underlying systemic disorders, such as myeloproliferative diseases and severe manifestations like anaphylaxis (2,3). Treatment of MPCM depends on the presence of systemic involvement and/or the clinical symptoms of the disease itself.
View Article and Find Full Text PDFHidradenitis suppurativa and psoriasis are considered chronic inflammatory diseases suggesting the existence of common pathogenetic pathways. We present two cases of comorbid psoriasis and hidradenitis suppurativa, treated with certolizumab pegol and brodalumab due to failure of response to other conventional therapies. Monoclonal antibody therapies have revolutionized the treatment of chronic inflammatory disorders such as psoriasis and hidradenitis suppurativa.
View Article and Find Full Text PDFSystemic sclerosis (SSc) is a progressively evolving multisystemic disorder of unknown etiology. Beyond skin, several other organs can also be affected with a severity of involvement that is often heterogeneous. We describe a 53-year-old female patient who was admitted urgently to the hospital almost collapsed, because of numerous bleeding deep skin ulcers, located all over the body.
View Article and Find Full Text PDFIn this report we briefly describe a 54-year-old woman who was referred to our institution for evaluation and management of newly diagnosed congestive heart failure associated with a skin rash. Detailed investigations revealed the presence of restrictive cardiomyopathy due to isolated primary cardiac amyloidosis as well as the presence of a skin disease named 'porokeratosis of Mibellli'. Interestingly, porokeratotic lesions rarely have been associated with localized cutaneous amyloidosis.
View Article and Find Full Text PDF